AXGN vs SYK: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
SYK is the larger of the two ($124.86B market cap): the incumbent the market prices for continued execution (19.43x forward earnings, beta 0.78). AXGN is the smaller challenger ($2.27B), actually pricier on forward earnings (61.94x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
AXGN vs SYK: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AXGN | SYK | What it tells you |
|---|---|---|---|
| Market cap | $2.27B | $124.86B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 61.94 | 19.43 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.09 | 0.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 86% of range | 39% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 8.84 | 5.43 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: SYK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how AXGN and SYK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AXGN and SYK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AXGN and SYK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Axogen (AXGN) do?
Axogen (AXGN) develops and sells products used by surgeons to repair and reconstruct peripheral nerves, the nerves outside the brain and spinal cord that carry signals to muscles and skin. Its portfolio centers on Avance, an acellular (processed human donor) nerve graft used to bridge gaps where a nerve has been cut, along with the Axoguard family of nerve connectors and protective wraps. These products are used in hand and upper-extremity trauma, breast reconstruction (restoring sensation), oral and facial surgery, and other reconstructive settings. Axogen sells through a specialized US sales force and reported full-year 2025 revenue of ~$225M, up ~20% year over year, with gross margins in the mid-70s percent range.
What does Stryker Corporation (SYK) do?
Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.
AXGN vs SYK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AXGN drivers: Avance FDA approval and exclusivity; Reimbursement tailwind.
- SYK drivers: Mako robotics and enabling technology; MedSurg and Neurotechnology breadth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Axogen is a small-cap medical device and biologics company, so the shares can be volatile and sensitive to quarterly results and guidance changes. For SYK, stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple.
AXGN or SYK: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AXGN if you believe its drivers more; SYK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AXGN and SYK guides.
AXGN vs SYK: the full fundamentals
AXGN. Axogen trades as a growth-oriented small-cap medtech, so its valuation reflects expected revenue expansion rather than current earnings, which have historically hovered near breakeven. The 2025 Avance approval and 2026 reimbursement increase reshaped the story, and the stock has been reactive to guidance updates. Figures are approximate and as of JULY 2026.
SYK. Stryker trades around $330 per share with a market cap near $127 billion, a premium franchise multiple that reflects its consistent growth record. Trailing P/E has run in the high-30s while the forward P/E sits closer to 22x on expected earnings growth. The Q1 2026 cyber incident dented near-term results, but management reaffirmed full-year organic growth guidance of 8.0% to 9.5%.
Headline figures (approximate, JULY 2026): AXGN shows revenue (fy2025) ~$225M, revenue growth (2025) ~20% YoY, gross margin ~74-76%, q1 2026 revenue ~$61.5M (up ~27% YoY); SYK shows revenue (2025) ~$25.1B, q1 2026 revenue ~$6.0B (+2.6% YoY), 2026 adj. eps guidance ~$14.90-$15.10, market cap ~$127B.
The bottom line: AXGN vs SYK
AXGN and SYK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AXGN and SYK exposure against your real portfolio. It is not an investment adviser.
Wondering how AXGN or SYK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Axogen with AI
Connect the broker you already use and ask Walnut's AI how AXGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AXGN and SYK?
+
Axogen (AXGN) develops and sells products used by surgeons to repair and reconstruct peripheral nerves, the nerves outside the brain and spinal cord that carry signals to muscles and skin. Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AXGN or SYK the better stock?
+
Neither is universally better. SYK is the larger incumbent; AXGN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AXGN or SYK?
+
On forward P/E (as of August 2026), AXGN trades at 61.94x and SYK at 19.43x, so SYK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AXGN and SYK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AXGN vs SYK?
+
AXGN: Axogen is a small-cap medical device and biologics company, so the shares can be volatile and sensitive to quarterly results and guidance changes. The business depends heavily on one core product franchise (Avance and Axoguard) and on a supply of processed human donor nerve tissue, which introduces concentration and supply risk. Reimbursement policy can move in either direction, and larger, better-capitalized competitors such as Integra LifeSciences, Stryker, and Baxter sell alternative conduits and wraps. The company has operated near breakeven on net income historically and has used equity offerings to fund the business, which can dilute shareholders. Adoption of nerve-repair procedures, clinical evidence, and consistent margin execution all remain uncertain. SYK: Stryker trades at a premium valuation, so any slowdown in organic growth or margin progress can pressure the multiple. Q1 2026 results were hurt by a late-quarter cyber incident that compressed adjusted margins and missed EPS estimates, and full recovery depends on catching up lost sales later in the year. The company faces strong competition in robotics and implants from Zimmer Biomet, Johnson & Johnson, Medtronic, and Smith and Nephew, plus pricing pressure from hospitals and payers. Integration risk from frequent acquisitions, currency swings, and regulatory or reimbursement changes add further uncertainty. Elective-procedure volumes can also be sensitive to macro and hospital-capacity conditions.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AXGN or SYK; figures are approximate and dated (as of August 2026). Verify current data before investing.